Acoramidis 356 mg Suppliers & Bulk Manufacturers

Available Forms: Tablet

Available Strengths: 356 mg

Reference Brands: Attruby(USA/EU), Beyonttra (UK)

Category: Heart Disorder

Acoramidis is a first-in-class oral transthyretin (TTR) stabilizer designed for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in adults. This rare and progressive heart condition can lead to heart failure and increased risk of cardiovascular death. Acoramidis works by stabilizing the TTR protein, preventing amyloid deposits in the heart, thereby reducing cardiovascular death and related hospitalizations.

Product Description:

Acoramidis is an oral transthyretin stabiliser. Transthyretin is a four-part protein that carries thyroxine and vitamin A; when it falls apart, the pieces misfold and deposit as amyloid in the heart, causing transthyretin amyloid cardiomyopathy. Acoramidis binds the protein and holds it together, mimicking a naturally occurring genetic variant that protects carriers from the disease. It achieves near-complete stabilisation, above 90%, which is the basis of its marketing position against the earlier stabiliser tafamidis.

In its pivotal trial it reduced a composite of death and cardiovascular hospitalisation over thirty months in patients with the wild-type or hereditary disease. It is taken twice daily with food. It is generally well tolerated; diarrhoea and upper abdominal pain are the most reported effects. Diagnosis requires bone scintigraphy or biopsy plus exclusion of light-chain amyloidosis, so the destination market needs that diagnostic pathway.

Sourcing notes. Originator product, on patent, with no generic. Approved in the US in 2024 and in the EU, UK and Brazil since, with different companies commercialising it inside and outside the US. Annual cost is high and access usually runs through specialist amyloidosis centres. Treat enquiries as authorised-distribution or named-patient supply.